Edition:
United States

Biohaven Pharmaceutical Holding Company Ltd (BHVN.N)

BHVN.N on New York Stock Exchange

21.01USD
8 Dec 2017
Change (% chg)

$0.22 (+1.06%)
Prev Close
$20.79
Open
$20.93
Day's High
$21.54
Day's Low
$20.14
Volume
128,769
Avg. Vol
52,779
52-wk High
$39.20
52-wk Low
$17.01

Chart for

About

Biohaven Pharmaceutical Holding Company Ltd. is a United States-based biopharmaceutical company. The Company is engaged in the identification and development of clinical-stage compounds targeting orphan neurologic indications and other neurological pathways. It has a portfolio of multiple late-stage drug candidates. Its pipeline... (more)

Overall

Beta: --
Market Cap(Mil.): $756.73
Shares Outstanding(Mil.): 36.02
Dividend: --
Yield (%): --

Financials

BRIEF-‍Biohaven receives agreement from FDA on initial pediatric study plan for rimegepant

Nov 20 Biohaven Pharmaceutical Holding Company Ltd-

Nov 20 2017

BRIEF-Biohaven Pharma qtrly loss per share $1.19‍​

Nov 14 Biohaven Pharmaceutical Holding Company Ltd

Nov 14 2017

BRIEF-Biohaven announces FDA clearance of IND application for sublingual BHV-0223

Nov 1 Biohaven Pharmaceutical Holding Company Ltd

Nov 01 2017

BRIEF-Biohaven appoints Clifford Bechtold as COO

Oct 25 Biohaven Pharmaceutical Holding Company Ltd

Oct 25 2017

BRIEF-Biohaven receives FDA may proceed letter for phase 2/3 clinical trial of Trigriluzole

Oct 24 Biohaven Pharmaceutical Holding Company Ltd

Oct 24 2017

BRIEF-Biohaven enters two separate subscription agreements with Kleo

Oct 12 Biohaven Pharmaceutical Holding Company Ltd

Oct 12 2017

BRIEF-Biohaven reports negative topline data from degenerative, genetic disease phase 2/3 trial

Oct 2 Biohaven Pharmaceutical Holding Company Ltd:

Oct 02 2017

BRIEF-Biohaven completes randomization in Phase 2/3 trial in spinocerebellar ataxia

Aug 7 Biohaven Pharmaceutical Holding Company Ltd

Aug 07 2017

Earnings vs. Estimates